



Eli Lilly and Company Limited
Lilly House
Priestley Road
Basingstoke
Hampshire
RG24 9NL
01256 315000

2018 Methodological Note – Eli Lilly and Company Limited – Transfers of Value

This note describes the methods used by Eli Lilly and Company Limited (“Lilly”) in the UK to meet its obligations and the requirements for disclosing payments and Transfers of Value (ToV) to Health Professionals (HCPs) and Healthcare Organisations (HCOs) as outlined in the EFPIA HCP/HCO Disclosure Code and reflected in the ABPI Code of Practice for the Pharmaceutical Industry.

This note excludes the requirements relating to Patient Organisations, as the reporting obligations for Patient Organisations are fulfilled in accordance with the EFPIA Patient Organisation Code.

All payments made in the reporting calendar year are included by Lilly in its report on ToV to HCP/HCOs (“UK Report”).

- Transfers of Value are reported in Great British Pounds (GBP).
- For **Contribution to Cost of Events**, the ToV date is equivalent to the day(s) relating to the event/meeting. Taxes and VAT are excluded (when administratively feasible) from the values reported here.
- Regarding **cross-border transfers**: the ToV for UK HCPs/HCOs across national borders is disclosed in the UK Report.
- If a payment was not made in GBP, conversion rates are used that are based on Lilly's financial rates at that time.

A. Definitions

- With respect to **HCP/HCO Definitions**, the ABPI definitions are followed, and any ToV provided to HCPs/HCOs are reported within the relevant categories. As per the ABPI guidance, other relevant decision makers are included in the UK Report.

B. Transfers of Value

- With respect to **Fee for Service** ToV, the ToV reported are the actual amounts reflecting the payment and related expenses.
- For **Contribution to Cost of Events** ToV, in order to generate the reported ToV averages are applied to registration fees, accommodation and group transports. For travel costs the actual costs of flights, rail and private transport are used. Complimentary registration fees are not used for the calculation of the average amounts. Complimentary accommodation is also not included in the average amounts for ToV.

C. Donations and Grants

- Donations and Grants to HCOs, in cash or in kind or otherwise (e.g., product donations) that are comprised of healthcare professionals and/or that provide healthcare, are included in the UK Report.

D. Sponsorship

- Sponsorship Agreements **with HCOs**, or Third parties appointed by HCOs to manage an Event organised by HCOs, are included in the UK Report. Medical Education Goods & Services are included for the UK.
- **Registration Fees** for Lilly Sponsored HCPs are disclosed in the HCP section of the UK Report. ToV is equal to the average amount of registration fees purchased by Lilly for HCP meeting attendees.
- **Travel** includes actual amounts for flights, rail and private transport; and average amounts for group transports.
- **Accommodation** ToV is equal to the average room rate for hotel rooms purchased by Lilly for HCP meeting attendees. ToV are reported in the HCP section of the UK Report.

E. Fees for Service and Consultancy

- HCP Fees for Service & Consultancy, Speaking & Consulting related engagements are included in the UK report.
- HCO Fees for Service & Consultancy, Consultancy related engagements such as Consultantships, Fellowships, Retrospective Non-Interventional Studies, Healthcare Partnerships and Educational Services are included in the UK Report.
- **Related Expenses** agreed as part of the fee for service or consultancy contract include miscellaneous travel and accommodation expenses relevant to the contract. These expenses are included in the UK Report, unless the related expense is part of the fee and it is not administratively feasible for this to be reported separately

F. Research & Development Disclosure

- This disclosure includes Transfers of Value to HCPs or HCOs related to the planning or conduct of:
 - (i) non-clinical studies (as defined in OECD Principles on Good Laboratory Practice); or,
 - (ii) clinical trials (as defined in Directive 2001/20/EC); or,
 - (iii) non-interventional studies that are prospective in nature and that involve the collection of patient data from, or on behalf, of individual or groups of HCPs specifically for the study.
- The disclosure includes both Lilly and Contract Research Organisation managed studies, and the ToV are included in the R&D section of the UK Report.

G. Joint Ventures/Co-Promotion

- When working with other pharmaceutical companies, such as in joint ventures or by co-promotion, Lilly will disclose ToV in this UK Report when Lilly is the contracting party and has made the ToV to the HCP/HCO.

H. Consent and Data Privacy

- Regarding **HCP/HCO Consent**, UK Data Protection Law requires Lilly to ask for consent from HCPs in order to disclose individual data. Lilly does not require HCPs to grant consent for individual disclosure in order to contract for services or for sponsorships. Lilly will disclose individual level payments when we have received consent to do so. If the HCP did not consent, then all ToV made to them are included in aggregate payment data. HCO consent is not required and therefore all ToV to HCOs are reported in full. HCPs have certain rights under the data protection laws and can withdraw their agreement for ToV data to be published under their name on the disclosure database. The UK report may be updated by Lilly to reflect changes in consent and correction of data.

I. Published Date

- The publication date of the UK Report is the date the current UK Report was generated via Lilly internal systems.